Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1969 3
1970 2
1971 1
1974 2
1976 1
1977 2
1978 2
1979 2
1981 1
1983 2
1984 1
1985 1
1986 3
1987 1
1988 1
1990 4
1991 2
1992 4
1993 7
1994 13
1995 7
1996 6
1997 8
1998 6
1999 6
2000 8
2001 14
2002 9
2003 8
2004 14
2005 22
2006 18
2007 22
2008 14
2009 24
2010 22
2011 27
2012 33
2013 21
2014 28
2015 29
2016 28
2017 38
2018 40
2019 32
2020 65
2021 54
2022 47
2023 42
2024 40

Text availability

Article attribute

Article type

Publication date

Search Results

717 results

Results by year

Filters applied: . Clear all
Page 1
Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U, Parakh S, Gan HK, Scott AM. Hafeez U, et al. Among authors: scott am. Molecules. 2020 Oct 16;25(20):4764. doi: 10.3390/molecules25204764. Molecules. 2020. PMID: 33081383 Free PMC article. Review.
Antibody therapy of cancer.
Scott AM, Wolchok JD, Old LJ. Scott AM, et al. Nat Rev Cancer. 2012 Mar 22;12(4):278-87. doi: 10.1038/nrc3236. Nat Rev Cancer. 2012. PMID: 22437872 Review.
Occupational therapy for cognitive impairment in stroke patients.
Gibson E, Koh CL, Eames S, Bennett S, Scott AM, Hoffmann TC. Gibson E, et al. Among authors: scott am. Cochrane Database Syst Rev. 2022 Mar 29;3(3):CD006430. doi: 10.1002/14651858.CD006430.pub3. Cochrane Database Syst Rev. 2022. PMID: 35349186 Free PMC article. Review.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, McJannett MM, Stockler MR, Violet JA, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Hofman MS, et al. Among authors: scott am. Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11. Lancet. 2021. PMID: 33581798 Clinical Trial.
TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models.
Meyran D, Zhu JJ, Butler J, Tantalo D, MacDonald S, Nguyen TN, Wang M, Thio N, D'Souza C, Qin VM, Slaney C, Harrison A, Sek K, Petrone P, Thia K, Giuffrida L, Scott AM, Terry RL, Tran B, Desai J, Prince HM, Harrison SJ, Beavis PA, Kershaw MH, Solomon B, Ekert PG, Trapani JA, Darcy PK, Neeson PJ. Meyran D, et al. Among authors: scott am. Sci Transl Med. 2023 Apr 5;15(690):eabk1900. doi: 10.1126/scitranslmed.abk1900. Epub 2023 Apr 5. Sci Transl Med. 2023. PMID: 37018415
FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy.
Chan JD, Scheffler CM, Munoz I, Sek K, Lee JN, Huang YK, Yap KM, Saw NYL, Li J, Chen AXY, Chan CW, Derrick EB, Todd KL, Tong J, Dunbar PA, Li J, Hoang TX, de Menezes MN, Petley EV, Kim JS, Nguyen D, Leung PSK, So J, Deguit C, Zhu J, House IG, Kats LM, Scott AM, Solomon BJ, Harrison SJ, Oliaro J, Parish IA, Quinn KM, Neeson PJ, Slaney CY, Lai J, Beavis PA, Darcy PK. Chan JD, et al. Among authors: scott am. Nature. 2024 May;629(8010):201-210. doi: 10.1038/s41586-024-07242-1. Epub 2024 Apr 10. Nature. 2024. PMID: 38600376 Free PMC article.
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, Francis RJ, Zhang AY, Scott AM, Lee ST, Azad AA, McJannett MM, Stockler MR, Williams SG, Davis ID, Hofman MS; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Buteau JP, et al. Among authors: scott am. Lancet Oncol. 2022 Nov;23(11):1389-1397. doi: 10.1016/S1470-2045(22)00605-2. Epub 2022 Oct 16. Lancet Oncol. 2022. PMID: 36261050 Clinical Trial.
717 results